SCHEMBL17916372

SCHEMBL17916372

CCc1ccc(C=O)c(OC)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TRIM24 O15164 1/20 0.37
▸ TYR P14679 1/20 0.37
▸ TRIM33 Q9UPN9 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ ERN1 O75460 7/20 0.35
▸ SRC P12931 2/20 0.35
▸ TUBB1 Q9H4B7 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ TSHR P16473 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ TLR2 O60603 1/20 0.33
▸ TLR1 Q15399 1/20 0.33
▸ TLR6 Q9Y2C9 1/20 0.33
▸ PDE3B Q13370 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17916367 0.88 CA1 (0.41) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL17919212 0.85 CA1 (0.47) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL29818698 0.82 CA1 (0.52) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL29818684 0.81 CA1 (0.44) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL27879245 0.80 CA1 (0.43) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL12797852 0.80 PTGS2 (0.37) ALDH1A1CYP2C19TSHRKDM4E
SCHEMBL10023121 0.79 CA1 (0.48) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL7178270 0.78 SRC (0.39) ALDH1A1L3MBTL1ERN1SRCTSHR
SCHEMBL29729025 0.77 CA1 (0.59) CA1CA2ALDH1A1L3MBTL1TRIM24
SCHEMBL3345839 0.77 CA1 (0.59) CA1CA2ALDH1A1L3MBTL1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090792-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-05-01 — — WO disclosed
US-20160200980-A1 LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200980-A1 LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD2, CNOT1, OCIAD1 CA1 557/4885CA2 952/4885ALDH1A1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback